ClinicalTrials.gg
RecruitingNCT07670650PRISE-hATGUpdated Nov 16, 2026

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

A Phase 3 interventional study of SAB-142 and Placebo in Type 1 Diabetes (T1D), sponsored by University of Florida. Recruiting at 4 sites in United States. Open to participants aged 5 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Florida · Phase 3, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
5 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Diabetes Mellitus, Type 1 by University of Florida — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Florida.

Planned enrollment
2nd of 14
108 · median 38
Started
2026
the only one that year
Phase 3
Only one
of the 18
Registered
18th of 18
by date

Among the 18 studies in Diabetes Mellitus, Type 1 by University of Florida, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 18 studies in Diabetes Mellitus, Type 1 by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 5 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetes Mellitus, Type 1 by University of Florida, or all of them as a file.
02

Study summary

This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with Stage 3 type 1 diabetes (T1D). The study will enroll participants with recent-onset T1D (>100 days to \<1 year from diagnosis) and established-onset T1D (≥1 year to ≤2 years from diagnosis) who retain residual beta-cell function as demonstrated by stimulated C-peptide levels >0.2 nmol/L. Participants will be randomized in a 2:1 ratio to receive SAB-142 or placebo in addition to standard diabetes care. The primary objective is to determine whether SAB-142 preserves beta-cell function over 12 months as measured by stimulated C-peptide response during a mixed meal tolerance test (MMTT). External data from the SAB-142-201 SAFEGUARD study will be incorporated to include participants with new-onset T1D (\<100 days from diagnosis) in the primary efficacy analysis.

Read the detailed description

Type 1 diabetes is an autoimmune disease characterized by progressive destruction of pancreatic beta cells. SAB-142 is a purified fully human multi-specific anti-thymocyte globulin designed to modulate autoimmune responses while potentially avoiding some of the immunogenicity and adverse effects associated with rabbit-derived anti-thymocyte globulin preparations. This study will evaluate whether SAB-142 preserves endogenous insulin production and improves clinical outcomes in participants with Stage 3 T1D who have residual beta-cell function.

The study consists of three disease-duration cohorts:

Cohort 1: New-onset T1D (\<100 days from diagnosis; external data from SAB-142-201 SAFEGUARD) Cohort 2: Recent-onset T1D (>100 days to \<365 days from diagnosis) Cohort 3: Established-onset T1D (365 to 730 days from diagnosis)

Approximately 72 participants will be enrolled into Cohorts 2 and 3 and randomized 2:1 to SAB-142 or placebo. An additional 36 age-matched participants from SAB-142-201 SAFEGUARD will comprise Cohort 1, resulting in a combined efficacy dataset of approximately 108 participants. Participants will receive an induction treatment period at baseline and a maintenance treatment period at Month 6. Follow-up continues through Month 12.

03

Conditions studied

  • Type 1 Diabetes (T1D)
04

Who can participate

Ages eligible
5 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant and/or appropriate legal guardian for participants below the legal age of consent must have given written and/or assent according to local, regional and/or country specific guidance before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Participants and legal guardians must be capable of providing informed consent and not be incapacitated.
  2. Males and females 5-40 years old*, inclusive, at the time of randomisation.

    * Note: Age step-down rules apply, as described in protocol Section 6.1.

  3. Weight ≥16.0 kg at time of randomisation. Participants age 18-40 will have a (BMI) between 16 to 32 (inclusive).
  4. Participant has received a diagnosis of T1D according to American Diabetes Association criteria (refer Section 22.1) as following:

    • For Cohort 2: within >100 days but \<1 year (365 days) of randomisation;
    • For Cohort 3: within ≥1 year (365 days) but \<2 years (730 days) of randomisation. For participants who were initially misdiagnosed with Type 2 diabetes (T2D), time from misdiagnosis with T2D to randomisation is up to 1 and 2 years.

    Note: Unless previously diagnosed with preclinical (Stage 1 or Stage 2 T1D), participant must have initiated insulin therapy the time of randomisation.

  5. Participant has random C-peptide levels of >0.2 nmol/L, measured during Screening. One random C-peptide retest during screening period is allowed.
  6. Participant completed all scheduled samples for C-peptide collected during the MMTT test during Screening.
  7. Participant has a positive result on testing for at least one of the following T1D-related autoantibodies during screening:

    • Glutamic acid decarboxylase 65 (GAD65)
    • Islet antigen 2 (IA-2)
    • Zinc transporter 8 (ZnT8)
    • Insulin autoantibodies (if testing within the first 14 days of insulin treatment)
  8. Female participants:

    1. Must be of nonchildbearing potential, i.e., pre-pubertal*, surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening, or (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle -stimulating hormone [FSH] level consistent with postmenopausal status, per local laboratory guidelines), or
    2. If of , must:

    i.Have a negative result on a serum (beta human chorionic gonadotropin [β-hCG]) at screening and a negative urine β-hCG pregnancy test prior to study drug administration on Day 1 of both treatment periods.

    ii.Agree not to become pregnant or donate ova from the time of signing the consent form until the end of the study visit.

    iii.If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception [Section 11.3.1]) from the time of signing the consent and for the duration of the study.

    * Note: Female participants will be considered to be pre-pubertal (and of nonchildbearing potential) if they have not yet started menstruation. This should also be verified by the parent(s)/guardian(s). If a female participant reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forwards, and contraceptive requirements will apply.

  9. Male participants, if not biologically or surgically sterilised, must:

    1. Agree not to donate sperm from the time of signing the consent form until End of Study (EOS).
    2. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception [refer to Section 11.3.1]) from the time of signing the consent form until EOS.
    3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from the time of signing the consent form until EOS.
  10. Prior to receiving study drug, participant must agree to receive locally, regionally and/or country-specific required age-appropriate immunisations. Participants are advised but not required to comply with the guidelines for individuals and those with chronic disease (diabetes mellitus) according to current local, regional and/or country-specific guidelines. Note: Vaccines are permitted within the timeframes specified in exclusion criterion #17.
  11. Participant agrees not to receive other forms of experimental treatment from the time of signing informed consent and for the duration of the study, particularly agents that may be immune modulatory in nature and/or stimulate pancreatic β cell regeneration or insulin secretion.
  12. Participant has suitable venous access for blood sampling.
  13. Participant is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Participant has known allergy, or moderate to severe allergic reaction including anaphylaxis to natural or recombinant antibodies, biologic treatments, passive vaccines, pork, or any other component of the study drug formulation (including biologic medications). This includes participants with Hereditary Fructose Intolerance.
  2. Participant has a known allergy or hypersensitivity to any of the protocol-required concomitant medications.
  3. Participant has been an active participant in a therapeutic drug, invasive medical device, or vaccine clinical trial within 12 weeks before Screening Visit (SV)2.
  4. Participant has received teplizumab or any immunomodulatory anti-CD3 treatment within any timeframe prior to screening.
  5. Participant has a significant uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, neurologic, haematologic, rheumatologic, oncologic, psychiatric, or immune deficiency that may interfere with the participant's safely participating in the study or with interpretation of the safety and/or efficacy profile of investigational medicinal product (IMP). For any disorders, a participant with a stable, well-controlled condition that is not felt to interfere with study participation may be enrolled.
  6. Participant has any disease other than T1D (e.g., latent autoimmune diabetes in adults, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, systemic lupus erythaematosis) that is currently managed with systemic immunotherapy, with the exception of clinically stable thyroid or celiac disease.
  7. Participant is prone to infections, or has chronic, recurrent or opportunistic infectious disease, including but not limited to renal, respiratory or skin infections, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis.
  8. Participant has a history of or serologic evidence at screening of current or past infection with (HIV)-1 or 2, virus (HBV), or virus (HCV) antibodies.
  9. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing. Note: Blood testing (e.g., QuantiFERON® TB Gold test) is strongly preferred; if not available, any local approved TB test is allowed.
  10. Serious systemic viral, bacterial, or fungal infection (e.g., pneumonia, pyelonephritis), infection requiring hospitalisation or IV anti-infective treatments or significant acute or chronic viral (including history of recurrent or active herpes zoster, acute or active CMV, EBV as determined at screening), bacterial, or fungal infection (e.g., osteomyelitis) 30 days before and during screening. Note: Participants with confirmed active EBV or CMV infection based on polymerase chain reaction (PCR) test can be retested; asymptomatic participants with the most recent PCR-negative (defined as PCR \<1000 copies/mL or its equivalent in plasma or serum based on the site-specific PCR assay) test are eligible for participation. Participants with an active mild infection at Screening may be enrolled once the symptoms have resolved and all I/E are met. Participants who have an active infection and/or fever ≥38.0°C (100.4°F) within the 48 hours prior to dose administration should not be dosed.
  11. Participant has a diagnosis of significant liver disease or at screening and/or AST >2× or total of >1.5× of the age- and sex-specific (ULN) according to the site laboratory and confirmed by repeated tests. Liver function tests can be repeated during screening and if normalised, participant may be eligible for randomisation. Note: Participants with Gilbert's syndrome are allowed to enrol if only total and/or indirect bilirubin are elevated above ULN while ALT, AST, and alkaline phosphatase (ALP) are within the normal laboratory ranges.
  12. An individual has any of the following haematologic parameters, confirmed by repeat tests, during Screening:

    • Lymphocyte count: \<1000/μL
    • : \<1500/μL
    • count: \<100 000 platelets/μL
    • : \<10 g/dL

    Note: Specific haematologic, oncologic or other systemic conditions that might otherwise result in exclusion and/or is heretofore unrecognised should be considered in individuals who have one or more blood cell counts below or above the references ranges.

  13. Current or prior (within 5× half-lives before SV2) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including systemic , verapamil, baricitinib, and others. Note: Inhaled and topical corticosteroids are allowed. Short courses, i.e., approximately 2 weeks or less, of systemic corticosteroids for transient conditions are allowed.
  14. Current or prior (within 5× half-lives before SV2) use of drugs other than insulin to treat hyperglycaemia (e.g., metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, glucagon-like peptide 1 agonists [glucagon-like peptide-1], dipeptidyl peptidase-4 [DPP-IV] inhibitors, or amylin).
  15. Current or prior (within 5× half-lives before SV2) use of any medication known to significantly influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, niacin).
  16. Current or planned highly restrictive dietary regimen(s) that would interfere with participant well-being or impact on the investigational drug.
  17. Recent or planned vaccinations as follows:

    Countries within the EU member states only:

    • (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox): from 30 days before dosing through 6 months following administration of SAB-142 for each TP;
    • Recombinant, inactivated or otherwise "non-live" vaccines: from 30 days before dosing or within 60 days following dosing; or planned/required within 30 days prior to or 60 days following Day 1 of TP2.
    • Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox): Within the 30 days before dosing or within 30 days following dosing; or planned/required within 30 days prior to or 30 days following Day 1 of each TP.
    • Recombinant, inactivated or otherwise "non-live" vaccines: Within the 30 days before dosing or within 30 days following dosing; or planned/required within 30 days prior to or 30 days following Day 1 of each TP.
  18. Female is lactating and/or plans to lactate with the intent to provide her own breast milk to a baby at any point during the study.
  19. An individual who has a history of alcohol, drug, or chemical abuse within 12 months prior to study screening (positive tetrahydrocannabinol is allowed) Note: Abuse is defined according to local, regional and/or country specific guidance. Participants who are tested positive for illicit substances but have a prescription medication to manage their concomitant conditions such as attention-deficit/hyperactivity disorder (ADHD) or others are allowed to participate in the study.
  20. An individual who has a medical, psychological or social condition that, in the opinion of the Investigator, would interfere with safe and proper completion of the trial.
  21. An individual who is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site. Note: Investigators should ensure that all study inclusion criteria and no study exclusion criteria have been met at screening. If a participant's clinical status changes (including any available laboratory results or receipt of additional medical records) after screening but before the first dose of study drug is given such that he or she no longer meets all eligibility criteria, then the participant should be excluded from participation in the study.
  22. An individual who is considered failing to thrive or extremely obese may be excluded based on assessment by the PI or if participation in the study may place the participant at risk.
  23. An individual who has been placed in an institution by official or court order.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    SAB-142

    SAB-142 in recent and established onset T1D

    Drug: SAB-142

  • Placebo comparator
    Placebo

    Placebo Comparator

    Drug: Placebo

Interventions

  • DrugSAB-142

    Treatment Period 1 (Induction) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 2.0 mg/kg IV Treatment Period 2 (Month 6 Maintenance) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 1.0 mg/kg IV Total induction dose: 2.5 mg/kg Total maintenance dose: 1.5 mg/kg

  • DrugPlacebo

    Placebo Comparator: Placebo

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)

    This is a measure of endogenous insulin production and β cell function (change from baseline in C-peptide ln \[AUC+1\].

    Time frame: Dose administration to 12 Months

Secondary outcomes

  1. AUC of C-peptide after a 2-hour MMTT in a priori in vitro identified "responders" and "non-responders"

    This is achange from baseline in C--peptide ln \[AUC+1\] at 12 months) in a priori in vitro identified "responders" and "non-responders" to SAB-142 and compared to placebo.

    Time frame: Baseline, Months 3, 6, 9 and 12

  2. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs).

    Time frame: Dose administration to 12 Months

  3. To evaluate the pharmacokinetics (PK) of SAB-142

    Evaluate SAB-142 serum concentrations over the infusion

    Time frame: Days 1 and 2 of each treatment period (pre- and post-dose/end of infusion [EOI]), plus Week 1 for TP1 (for participants that attend the optional in-clinic visit), Week 4, and Months 3, and 7.

  4. To evaluate the immunogenicity of SAB-142

    Incidence and titres of anti-SAB-142 antibodies in serum including neutralising antibodies (nAbs) if indicated.

    Time frame: Baseline, Week 1 (for participants that attend the optional in-clinic visit), Week 4, Months 3, 6, 7, 9, and 12.

  5. Immunophenotyping following SAB-142 administration will be performed on PBMC using flowcytometry

    Changes in immune cell populations following SAB-142 administration will be performed on PBMC using flowcytometry. All data will be reported as a percentage of lymphocytes and compared to baseline analysis. Populations to be tested: * CD3+CD4+ Tcells * CD3+CD8+ Tcells * CD19+ Bcells

    Time frame: Baseline (Day 1, pre-dose), Week 4, Months 3, 6, 7, 9 and 12.

  6. Haemoglobin A1c (HbA1c) levels

    Hba1c is a key clinical parameter for looking at improvement in type 1 diabetes .Expressed in % and mmol/molmanagement

    Time frame: Baseline, Months 3, 6, 9 and 12

  7. Time in Range (TIR)

    Expressed as a daily average of the percentage of time in a 24-hour day a participant's CGM reading is \>70 but ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L), assessed by CGM

    Time frame: Baseline, Months 3, 6, 9 and 12

  8. Improvement in Time in Tight Range (TITR)

    Expressed as a daily average of the percentage of time in a 24hour day a participant's glucose is \>70 but ≤140 mg/dL (\>3.9 to ≤7.8 mmol/L), assessed using continuous glucose monitoring (CGM)

    Time frame: Baseline, Months 3, 6, 9 and 12

  9. Improvement in Time Below Range on a Continuous Glucose Monitor

    Time Below Range on a continuous glucose monitor is a key clinical indicator for improvement in type 1 diabetes management

    Time frame: Baseline, Months 3, 6, 9 and 12

  10. Improvement in Time Above Range on a Continuous Glucose Monitor

    Time Above Range on a continuous glucose monitor is a key clinical indicator for improvement in type 1 diabetes management

    Time frame: Baseline, Months 3, 6, 9 and 12

  11. Number of clinically important hypoglycemic episodes

    Defined as the total number of Level 2 and 3 hypoglycaemic events and/or episodes of cognitive impairment requiring external assistance for recovery (participant's diary and CGM-based).

    Time frame: Baseline, Months 3, 6, 9 and 12

  12. Exogenous Insulin use

    Defined as a daily average in units per kilogram per day (U/kg/day) (total daily insulin based on participant's diary at predefined study periods).

    Time frame: Baseline, Months 3, 6, 9 and 12

  13. Proportion of participants with partial clinical remission

    Defined as an insulin requirement of \<0.25 units per kg of body weight per day and HbA1c \<6.5% (47 mmol/mol).

    Time frame: Baseline, Months 3, 6, 9 and 12

  14. Proportion of participants with partial remission

    Defined as insulin-dose adjusted A1c (IDAA1c) + \[4 × insulin dose (units per kilogram per 24 h) ≤9

    Time frame: Baseline, Months 3, 6, 9 and 12

  15. Total BETA-2 score

    A score comprised of fasting plasma glucose (mmol/L), HbA1c (%), daily insulin (U/kg), and fasting C-peptide (nmol/L)

    Time frame: Baseline, Months 3, 6, 9 and 12

  16. Insulin dose-adjusted A1c (IDAA1C)

    Time frame: Baseline, Months 3, 6, 9 and 12

Other outcomes

  1. C-peptide quantitative response (QR) metric

    Time frame: Baseline, Months 3, 6, and 12.

  2. 2-hour MMTT C-peptide AUC

    Time frame: Baseline, Months 3, 6, and 12.

  3. Fasting C-peptide

    Time frame: Baseline, Months 3, 6, 9, and 12.

  4. Proportion of participants maintaining a clinically significant stimulated peak C-peptide of ≥0.2 nmol/L during the 2-hour MMTTs

    Time frame: Baseline, Months 3, 6, and 12.

  5. Fasting proinsulin-to-C-peptide ratio, a measure of β cell endoplasmic reticulum stress and dysfunction

    Time frame: Baseline, Months 3, 6, 9, and 12.

  6. Calculated estimated residual stimulated C-peptide (CPEST)

    Time frame: Baseline, Months 3, 6, 9, and 12.

  7. Proportion of participants with poor glycaemic control, defined as HbA1c of ≥9%

    Time frame: Baseline, Months 3, 6, 9, and 12.

  8. The number of participants who do not require exogenous insulin because they are able to achieve local, regional, or national age-based glycaemic management goals for HbA1c and/or routine blood glucose levels

    Time frame: Baseline, Months 3, 6, 9, and 12.

  9. Incidence of Level 1, 2, and Level 3 hypoglycaemia during the CGM reporting periods

    Time frame: Baseline, Months 3, 6, 9 and 12

  10. Incidence of diabetic ketoacidosis requiring medical attention

    Incidence of diabetic ketoacidosis requiring medical attention, defined as a hyperglycaemic episode with serum or urine ketones elevated beyond upper limit of normal along with serum bicarbonate ≤18 mmol/L or blood pH ≤7.3, or both, and resulting in outpatient, emergency room visit or hospitalisation

    Time frame: Baseline, Months 3, 6, 9 and 12

  11. Participants with both HbA1c and exogenous insulin doses in range

    Participants with both HbA1c in the American Diabetes Association target range (i.e., \<7.5%) and exogenous insulin dose in specific ranges (\<0.25, 0.25 to \<0.50, 0.50 to \<0.75, 0.75 to \<1.0, 1.0 to \<1.25, and ≥1.25 U/kg/day)

    Time frame: Baseline, Months 3, 6, 9, and 12.

  12. Patient- and parent-reported outcomes (PROs)

    Patient-reported outcomes: oAge-appropriate Diabetes Treatment Satisfaction Questionnaire (DTSQ) o Age-appropriate PedsQL TM Diabetes Module Version 3.2 o Parent reports for DTSQ (to be completed by caregivers \[if available\]) of participants \<18 years old

    Time frame: Baseline, Months 6 and 12

  13. Changes in serum cytokine IL-2

    Changes in serum cytokine IL-2 reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  14. Changes in serum cytokine IL-4

    Changes in serum cytokine IL-4 reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  15. Changes in serum cytokine IL-6

    Changes in serum cytokine IL-6 reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  16. Changes in serum cytokine IL-10

    Changes in serum cytokine IL-10 reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  17. Changes in serum cytokine IL-12

    Changes in serum cytokine IL-12 reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  18. Changes in serum cytokine IL-17A

    Changes in serum cytokine IL-17A reported in pg/mL

    Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.

  19. Ex vivo safety immune functional assay: ELIspot Assay based on the PBMC samples

    This assay is a sensitive, quantitative method used to assess PBMC function to release cytokines following administration of an investigational drug by measuring antigen-specific cytokine secretion at the single-cell level. PBMCs collected at defined timepoints (e.g., pre- and post-dose) are stimulated ex vivo, and IFN-γ or IL-13 cytokines released by activated cells are captured on antibody-coated plates, forming spots that correspond to individual responsive cells (reported as spot-forming units). Changes in spot frequency and cytokine profile relative to baseline provide a functional readout of drug effect, enabling evaluation of immune activation, suppression, or polarization, and supporting pharmacodynamic, dose-response, and mechanism-of-action assessments in clinical studies.

    Time frame: Baseline, and Months 3, 6, 9, and 12

  20. Immune assays 1

    Functional exhaustion assay oActivation induced marker (AIM) assay

    Time frame: Baseline, Week 4, Months 6 and 12

  21. Neutrophil assay

    Time frame: Baseline, Months 6 and 9

  22. PBMCs

    Ex vivo treatment of pre-dose peripheral blood mononuclear cells (PBMCs)

    Time frame: Baseline

  23. IPT

    Whole blood sample for IPT

    Time frame: Baseline, Week 4, Month 3, Month 6, Month 7, Month 9, and Month 12.

  24. Single nucleotide polymorphism (SNP) analysis

    Single Nucleotide Polymorphism analysis will be reported as a genetic marker profile of T1D risk variants to to potentially identify treatment responders and non-responders post-hoc.

    Time frame: Baseline

  25. DNA methylation and RNA-sequencing

    DNA methylation will be reported as an epigenetic profile to potentially identify treatment responders and non-responders post-hoc. RNA-sequencing will be reported as a longitudinal profile of single cell immune transcriptome changes over time to potentially identify treatment responders and non-responders post-hoc.

    Time frame: Baseline, Months 6 and 9

  26. microRNA expression

    Clinical serum samples will be collected according to the SAB-142-201 protocol and Laboratory Manual. The data will reported as a risk profile of miRNAs will be used to explore predictivity of responder or non-responder outcomes.

    Time frame: Baseline, Months 3, 6 and 9

07

Study locations

1 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Mar 2029, 27 months after the start.

Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 27 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 26, 2026
StartActual
Nov 10, 2026was Sep 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Sep 1, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
Show 4 sites
  • University of California San Francisco Benioff Children's Hospital · San Francisco, United Statesno status→Not yet recruiting
  • Barbara Davis Center for Diabetes · Aurora, United Statesno status→Not yet recruiting
  • University of Florida · Gainesville, United Statesno status→Recruiting
  • IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology · Indianapolis, United Statesno status→Not yet recruiting
Nov 16, 2026
Start date
Sep 1, 2026→Nov 10, 2026 (actual)
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Barbara Davis Center for Diabetes · Aurora, United StatesContact added k•••@cuanschutz.edu · •••1055
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
    Show 4 sites
    • University of California San Francisco Benioff Children's Hospital · San Francisco, United Statesno status→Not yet recruiting
    • Barbara Davis Center for Diabetes · Aurora, United Statesno status→Not yet recruiting
    • University of Florida · Gainesville, United Statesno status→Recruiting
    • IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology · Indianapolis, United Statesno status→Not yet recruiting
    Start date Sep 1, 2026→Nov 10, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Barbara Davis Center for Diabetes · Aurora, United StatesContact added k•••@cuanschutz.edu · •••1055
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07670650
Collaborators
SAb Biotherapeutics, Inc., Breakthrough T1D
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Nov 10, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Michael JH Haller, MD
Contact
hallemj@peds.ufl.edu
(352) 273-9264
Laura M Jacobsen
Contact
lauraj@ufl.edu
(352) 265-7337

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion